DGAP-News: INJEX Pharma AG: INJEX Pharma AG is thrilled to announce the registration of INJEX Pharma USA in Miami, Florida. This will allow INJEX Pharma to begin the sale and marketing of the needle free injection device INJEX 30 in the USA.
(firmenpresse) - DGAP-News: INJEX Pharma AG / Key word(s): Product Launch
INJEX Pharma AG: INJEX Pharma AG is thrilled to announce the
registration of INJEX Pharma USA in Miami, Florida. This will allow
INJEX Pharma to begin the sale and marketing of the needle free
injection device INJEX 30 in the USA.
09.03.2012 / 10:28
---------------------------------------------------------------------
INJEX Pharma AG ISIN:DE000A0STYL7
Berlin, 09. March 2012
Marketing and sales of the innovative injection without needle INJEX, is
expected to begin in the spring 2012. Our new office is expected to open
soon.
The USA market is huge, with more than 40 million diabetics, 250,000
dentists, 500,000 MD's and 180,000 beauticians. The new company will create
strong affiliations with solid distribution partners in the US.
Negotiations were started months ago and it is expected, that first orders
will be delivered in the next months.
The INJEX 30 is a CE approved medical device and the company will announce
shortly corporate news about the FDA 510(k) registration.
The new INJEX Pharma USA is headed by International Sales Director, Mr.
Sylwin Grinman, who has been responsible for acquiring new exclusive
distributor agreements, which was signed for in other big markets like
China, India, Brazil, Canada etc.
According to Mr. Grinman:
'USA/ North America is a powerful market for any new and unique technology
that wants to establish its potential in its respective marketplace.
We are blessed to have the INJEX technology. This needle free injection
system will create remarkable changes for all people who fear needles and
alleviate the stress and anxiety associated with traditional needle and
syringe. Its applications are numerous and constantly emerging, ranging
from dentistry, doctors who use local anesthesia, cosmetology, diabetics
who use insulin or other medication that is self-administered, such as
growth hormones and heparin. INJEX is a high technology device. It is
simple, easy to use and will fit perfectly into the American lifestyle.'
press contact:
Maysmedia
Am Ideck 28
D-42781 Haan
0049-2129-343439
germany(at)maysmedia.de
contact:
Andy Rösch
CEO / Managing Director
INJEX Pharma AG
Buckower Damm 114
12349 Berlin
Tel.: 030/53096768
andy.roesch(at)injex.com
www.injex.com
End of Corporate News
---------------------------------------------------------------------
09.03.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
159967 09.03.2012
Themen in dieser Pressemitteilung:
injex-pharma-ag-injex-pharma-ag-is-thrilled-to-announce-the-registration-of-injex-pharma-usa-in-miami
florida-this-will-allow-injex-pharma-to-begin-the-sale-and-marketing-of-the-needle-free-injection-device-injex-30-in-the-usa
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="LAMBDA TD Software Increases Revenue in 4th Quarter 2011
Datum: 09.03.2012 - 10:28 Uhr
Sprache: Deutsch
News-ID 123221
Anzahl Zeichen: 3297
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: INJEX Pharma AG: INJEX Pharma AG is thrilled to announce the registration of INJEX Pharma USA in Miami, Florida. This will allow INJEX Pharma to begin the sale and marketing of the needle free injection device INJEX 30 in the USA."
steht unter der journalistisch-redaktionellen Verantwortung von
INJEX Pharma AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
